SVS.V - Solarvest BioEnergy Inc.
| Previous Close | 0.0800 |
| Open | 0.0800 |
| Bid | 0.0750 x N/A |
| Ask | 0.1000 x N/A |
| Day's Range | 0.0800 - 0.0800 |
| 52 Week Range | 0.0150 - 0.2500 |
| Volume | 5,000 |
| Avg. Volume | 17,455 |
| Market Cap | 3.144M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
FSD Pharma and Solarvest Enhance Commitment to CBD Research Project
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma") and Solarvest BioEnergy Inc. (TSX-V: SVS) ("Solarvest") (collectively, the "Parties"), are pleased to announce that, further to their press release of May 7, 2019, the Parties have agreed to amendments to the Collaborative Research and Development Agreement (the "Research Agreement") designed to accelerate progress of the research project that Solarvest is carrying out (the "CBD Research Project"). Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares ("FSD Shares") to Solarvest, which will enable Solarvest to fund the CBD Research Project. In addition, Solarvest has appointed Dr. Edward J. Brennan, Jr., M.D., FACS ("Dr. Brennan"), currently the President of FSD Pharma’s BioSciences Division, to the board of directors of Solarvest.
- Simply Wall St.
Imagine Owning Solarvest BioEnergy (CVE:SVS) And Wondering If The 28% Share Price Slide Is Justified
For many, the main point of investing is to generate higher returns than the overall market. But the main game is to...
CNW GroupFSD Pharma Announces Research Agreement with Solarvest to Develop Algae-based, Pharma-grade Cannabinoids
TORONTO, May 7, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTC:FSDDF - News) (FRA: 0K9) ("FSD Pharma" or "FSD") and Solarvest BioEnergy Inc. (TSX-V:SVS.V - News) ("Solarvest"), a technology company that developed an algal-based flexible production platform capable of producing health products, announced today that they signed a definitive collaborative research and development agreement. Under the agreement, Solarvest will conduct research using its algal expression technology to develop pharmaceutical-grade cannabinoids. FSD Pharma and Solarvest have made investments into one another and FSD has the option to enter into an exclusive license arrangement over a subset of the project and receive royalty rights over all of the products that result from the project.
